Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Perry

Showing results (71-80 of 82) with videos related to

Pageof 9
Sort By:
Journal of Neuro-Ophthalmology : the Official Journal of the North American Neuro-Ophthalmology Society|April 14, 2022
Expert Consensus on the Use of Teprotumumab for the Management of Thyroid Eye Disease Using a Modified-Delphi ApproachRaymond S Douglas, Andrea L Kossler, Jody Abrams, et al.
Alzheimer'S Research & Therapy|October 27, 2017
The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer's diseaseCraig W Ritchie, Tom C Russ, Sube Banerjee, et al.
Alzheimer'S Research & Therapy|August 1, 2018
Correction to: The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer's diseaseCraig W Ritchie, Tom C Russ, Sube Banerjee, et al.
Journal of Neurology|June 11, 2020
Platelet function/reactivity testing and prediction of risk of recurrent vascular events and outcomes after TIA or ischaemic stroke: systematic review and meta-analysisSoon Tjin Lim, Vincent Thijs, Stephen J X Murphy, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|December 13, 2025
Lecanemab appropriate use recommendations for clinical practice in the UKCatherine J Mummery, Jill Rasmussen, Dan Blackburn, et al.
JAMA Neurology|May 26, 2018
Use of Flutemetamol F 18-Labeled Positron Emission Tomography and Other Biomarkers to Assess Risk of Clinical Progression in Patients With Amnestic Mild Cognitive ImpairmentDavid A Wolk, Carl Sadowsky, Beth Safirstein, et al.
The Lancet. Neurology|October 18, 2024
Tenecteplase versus alteplase for acute stroke within 4·5 h of onset (ATTEST-2): a randomised, parallel group, open-label trialKeith W Muir, Gary A Ford, Ian Ford, et al.
European Stroke Journal|January 28, 2020
Therapeutic hypothermia for acute ischaemic stroke. Results of a European multicentre, randomised, phase III clinical trialH Bart van der Worp, Malcolm R Macleod, Philip Mw Bath, et al.
Toxicologic Pathology|June 14, 2011
An analysis of pharmaceutical experience with decades of rat carcinogenicity testing: support for a proposal to modify current regulatory guidelinesFrank D Sistare, Daniel Morton, Carl Alden, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|February 19, 2008
Interlaboratory evaluation of genomic signatures for predicting carcinogenicity in the ratMark R Fielden, Alex Nie, Michael McMillian, et al.
Pageof 9

Showing results (71-80 of 82) with videos related to

Sort By:
Pageof 9
Journal of Neuro-Ophthalmology : the Official Journal of the North American Neuro-Ophthalmology Society|April 14, 2022
Expert Consensus on the Use of Teprotumumab for the Management of Thyroid Eye Disease Using a Modified-Delphi ApproachRaymond S Douglas, Andrea L Kossler, Jody Abrams, et al.
Alzheimer'S Research & Therapy|October 27, 2017
The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer's diseaseCraig W Ritchie, Tom C Russ, Sube Banerjee, et al.
Alzheimer'S Research & Therapy|August 1, 2018
Correction to: The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer's diseaseCraig W Ritchie, Tom C Russ, Sube Banerjee, et al.
Journal of Neurology|June 11, 2020
Platelet function/reactivity testing and prediction of risk of recurrent vascular events and outcomes after TIA or ischaemic stroke: systematic review and meta-analysisSoon Tjin Lim, Vincent Thijs, Stephen J X Murphy, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|December 13, 2025
Lecanemab appropriate use recommendations for clinical practice in the UKCatherine J Mummery, Jill Rasmussen, Dan Blackburn, et al.
JAMA Neurology|May 26, 2018
Use of Flutemetamol F 18-Labeled Positron Emission Tomography and Other Biomarkers to Assess Risk of Clinical Progression in Patients With Amnestic Mild Cognitive ImpairmentDavid A Wolk, Carl Sadowsky, Beth Safirstein, et al.
The Lancet. Neurology|October 18, 2024
Tenecteplase versus alteplase for acute stroke within 4·5 h of onset (ATTEST-2): a randomised, parallel group, open-label trialKeith W Muir, Gary A Ford, Ian Ford, et al.
European Stroke Journal|January 28, 2020
Therapeutic hypothermia for acute ischaemic stroke. Results of a European multicentre, randomised, phase III clinical trialH Bart van der Worp, Malcolm R Macleod, Philip Mw Bath, et al.
Toxicologic Pathology|June 14, 2011
An analysis of pharmaceutical experience with decades of rat carcinogenicity testing: support for a proposal to modify current regulatory guidelinesFrank D Sistare, Daniel Morton, Carl Alden, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|February 19, 2008
Interlaboratory evaluation of genomic signatures for predicting carcinogenicity in the ratMark R Fielden, Alex Nie, Michael McMillian, et al.
Pageof 9